BJMO - volume 19, issue 2, march 2025
W. Lybaert MD, C. Jacobs MD, C. Fontaine MD, L. Mortier MD, S. Derijcke MD, T. Wessels MD, A. Aerssens MD
In recent years, our armamentarium for oncological diseases has rapidly evolved; treatment modalities include surgery, radiotherapy, chemotherapy, targeted therapy, hormonal treatments, immunotherapy, and recently the antibody-drug conjugates (ADC). All these treatments have more or less consequences for the immune system of our patients, above the cancer itself, which causes a state of immunosuppression.
(BELG J MED ONCOL 2025;19(2):61–62)
Read more
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
